Skip to search formSkip to main contentSkip to account menu

EZN 3042

Known as: Survivin mRNA Antagonist EZN-3042, EZN-3042, EZN3042 
A locked nucleic acid (LNA) antisense oligonucleotide targeting survivin mRNA, with potential antineoplastic activity. EZN-3042 hybridizes to… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Oligonucleotides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Phase-I trial of survivin inhibition with EZN-3042 in dogs with spontaneous lymphoma
Background Lymphoma is a common cancer in dogs. While most dogs receiving chemotherapy experience remission, very few are cured… 
2016
2016
Survivin inhibition via EZN-3042 in canine lymphoma and osteosarcoma.
Canine lymphoma (LSA) and osteosarcoma (OS) have high mortality rates and remain in need of more effective therapeutic approaches… 
2014
2014
A Phase I Study of EZN-3042, a Novel Survivin Messenger Ribonucleic Acid (mRNA) Antagonist, Administered in Combination With Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL…
To address the therapeutic challenges in childhood relapsed ALL, a phase 1 study combining a survivin mRNA antagonist, EZN-3042… 
2013
2013
Mycobacterium abscessus diagnosed in hemoculture
A 23 y/o female admitted with complaints of fewer, dyspnea, and cough for a month. She was diagnosed systemic lupus erytematotus… 
2013
2013
Abstract 31: A population pharmacokinetic-pharmacodynamic (POP-PK/PD) modelling of EZN-3042 administered with or without docetaxel in patients with advanced solid tumors or lymphoma.
Background: Survivin, a member of the apoptosis protein inhibitor family, is an essential regulator of cell division and a… 
Highly Cited
2011
Highly Cited
2011
Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia.
Relapse of drug-resistant acute lymphoblastic leukemia (ALL) has been associated with increased expression of survivin/BIRC5, an… 
2011
2011
Abstract LB-409: Results of a phase 1, open-label, dose-escalation study evaluating the safety and tolerability of EZN-3042, a survivin mRNA antagonist, administered with or without docetaxel in…
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Background : Survivin, the smallest member of the… 
2011
2011
Results of a Phase 1, open-label, dose-escalation study evaluating the safety and tolerability of EZN-3042, a survivin messenger ribonucleic acid (mRNA) antagonist, administered with or without…
A th W T l h 1 A it P t ik 1 K i k P P d l 1 J A 1 F i M L ki 2 K R ï 2 St K l b k † Ab B hbi d 3* Poster A216 n ony . o c er, m… 
2010
2010
Down-Modulation of Survivin Expression and Inhibition of Tumor Growth In Vivo by EZN-3042, A Locked Nucleic Acid Antisense Oligonucleotide
Survivin plays an important role in preventing apoptosis and permitting mitosis, and is highly expressed in various human cancers… 
2008
2008
A novel locked nucleic acid oligonucleotide against survivin, EZN-3042, inhibits survivin expression and causes antitumor effects
1) EZN-3042 displayed potent in vitro knockdown of survivin mRNA and growth inhibition of several human cancer cell lines (IC50… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)